Stocks and Investing Stocks and Investing
Mon, July 24, 2023

Matthew Korn Reiterated (BNTX) at Hold and Held Target at $119 on, Jul 24th, 2023


Published on 2024-10-28 05:04:02 - WOPRAI, Matthew Korn
  Print publication without navigation


Matthew Korn of Morgan Stanley, Reiterated "BioNTech SE" (BNTX) at Hold and Held Target at $119 on, Jul 24th, 2023.

Matthew has made no other calls on BNTX in the last 4 months.



There are 10 other peers that have a rating on BNTX. Out of the 10 peers that are also analyzing BNTX, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold with Decreased Target to $120 on, Thursday, May 18th, 2023
  • Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $128 on, Monday, April 10th, 2023
  • Eliana Merle of "UBS" Maintained at Hold with Decreased Target to $153 on, Friday, March 31st, 2023
  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Decreased Target to $140 on, Tuesday, March 28th, 2023
  • Yaron Werber of "TD Cowen" Maintained at Hold with Decreased Target to $130 on, Tuesday, March 28th, 2023


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Rajesh Kumar of "HSBC" Initiated at Strong Buy and Held Target at $124 on, Friday, July 14th, 2023
  • Bill Selesky of "Canaccord Genuity" Reiterated at Strong Buy and Held Target at $203 on, Friday, June 16th, 2023
  • Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $181 on, Friday, June 9th, 2023
  • Simon Baker of "Redburn Partners" Upgraded from Hold to Strong Buy and Increased Target to $170 on, Wednesday, May 17th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $194 on, Tuesday, March 28th, 2023
Contributing Sources